SEC Filings
Entrada Narrows Quarterly Loss To $39.7 Million And Extends Funding Horizon Into 2027
Lower research costs helped trim the loss as Entrada prepares for four expected clinical readouts through the first half of 2027.
Entrada Therapeutics (TRDA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Lower research costs helped trim the loss as Entrada prepares for four expected clinical readouts through the first half of 2027.
SEC Filings
Cohort 2 at a doubled 10 mg/kg dose is fully enrolled, with data targeted for the first half of 2027.